EP2768525A1 - Formulations d'étanercept stabilisées par des ions métalliques - Google Patents

Formulations d'étanercept stabilisées par des ions métalliques

Info

Publication number
EP2768525A1
EP2768525A1 EP12842352.2A EP12842352A EP2768525A1 EP 2768525 A1 EP2768525 A1 EP 2768525A1 EP 12842352 A EP12842352 A EP 12842352A EP 2768525 A1 EP2768525 A1 EP 2768525A1
Authority
EP
European Patent Office
Prior art keywords
composition
etanercept
less
peak
hic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12842352.2A
Other languages
German (de)
English (en)
Other versions
EP2768525A4 (fr
EP2768525B1 (fr
Inventor
Mark Manning
Brian Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherus Biosciences Inc
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Priority to RSP20190864 priority Critical patent/RS59179B1/sr
Priority to SI201231635T priority patent/SI2768525T1/sl
Priority to PL12842352T priority patent/PL2768525T3/pl
Publication of EP2768525A1 publication Critical patent/EP2768525A1/fr
Publication of EP2768525A4 publication Critical patent/EP2768525A4/fr
Application granted granted Critical
Publication of EP2768525B1 publication Critical patent/EP2768525B1/fr
Priority to HRP20191215TT priority patent/HRP20191215T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to aqueous pharmaceutical compositions stabilized with metal ions for long-term storage of etanercept, methods of manufacture of the compositions, methods of their administration, and kits containing the same.
  • the invention includes etanercept formulations that do not require arginine for stabilization.
  • Polypeptides must often be stored prior to their use. When stored for extended periods, polypeptides are frequently unstable in solution (Manning et al., 1989, Pharm. Res. 6:903-918). To extend their she!f life, additional processing steps have been developed, such as drying, e.g., lyophilization. However, lyophilized pharmaceutical compositions are less convenient to use.
  • Typical practices to improve polypeptide stabilit can be addressed by varying the concentration of elements with the formulation, or by adding excipients to modify the formulation (See, for example, U.S. Pat. Nos. 5,580,856 and 6,171 ,586).
  • the use of additives can still result in inactive polypeptides.
  • the rehydration step can result in inactivation of the polypeptide by, for example, aggregation or denaturation (Hora et al., 1992, Pharm. Res., 9:33-36; Liu et al., 1991 , Biotechnol. Bioeng., 37:177-184).
  • etanercept (Enbrel®, Immunex Corporation), which is a dimeric fusion polypeptide consisting of the extracellular ligand-binding portion of the human 75 kilodaiton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human SgG1, it consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons (Physicians Desk Reference, 2002, Medical Economics Company Inc.)
  • the Fc component of eianercept contains the constant heavy 2 (CH2) domain, the constant heavy 3 (CH3) domain and hinge region, but not the constant heavy 1 (CH1) domain of human IgGL
  • An Fc domain can contain one or ail of the domains described above.
  • Eianercept is usually produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.
  • the present invention provides novel stable liquid formulations of etanercept that allow its long-term storage.
  • the present invention is an aqueous pharmaceutical composition
  • a aqueous pharmaceutical composition comprising etanercept and a stabilizer to inhibit instability, aggregation, misfolding and/or fragmentation of the etanercept, wherein the stabilizer comprises a stabilizing metal ion.
  • the stabilized etanercept formulations of the present invention elicit long term storage stability as characterized by at least one of: (1) SEC analysis at M3 or T 2 or T of: monomer content greater than about 90%; aggregates content of less than about 3 wt%; and fragment 3 content less than about 5 wt%: and (2) HIC analysis at 3 or T 2 or T wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt.%.
  • the etanercept formulations containing metal ions elicit long term storage stability as characterized by: (1) SEC analysis at M 3 or T 2 or T 4 of greater than about 90 wt.% monomer content; less than about 3 wt.% aggregate(s) content; and less than about 5 wt% fragment 3; and (2) HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt.%; the amount of the composition represented by peak 2 of the H!C chromatogram is greater than 80 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt.%.
  • the formulations elicit long term storage stability as characterized by: an HIC analysis at lv1 ⁇ 2 or T 2 or T 4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt.%; and wherein, if peak 3 is present on the HiC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt.%.
  • the stabilized etanercept formulation as summarized above optionally and preferably, contain no arginine, or are essentially free of arginine.
  • the formulations of the invention have excellent stability as determined by ize Exclusion Chromatography) and HIC (Hydrophobic Interaction Chromatography) analysis conducted after one, two or three months of storage at 5° C. These formulations are comparable to or better than a commercially available formulation of etanercept, in which arginine is a required component.
  • the present invention is further directed to formulations of etanercept, stabilized with metal ions which contain no arginine, or are essentially free of arginine, and wherein the composition, at M 3 or T 2 or T 4 , elicits long term storage stability that meets one or both of the following criteria: (A) stability comparable to or better than commercially available etanercept marketed under the trademark Enbrel®, as measured by (i) SEC analysis of the amounts of aggregate(s), monomer and fragment 3 in the composition (as defined in the specification) and (ii) HIC analysis of amounts of material in the composition corresponding to peaks 1 , 2 and 3 of the HIC chromatogram (as defined in the specification); and (B) an HIC chromatogram in which (i) peak 3 is absent, or essentially absent and (ii) peak 2 represents greater than about 95 wt% of the composition; an SEC chromatogram containing essentially no peak corresponding to aggregafe(s): and an SEC chromatogram
  • Formulations of the present invention are able to meet the foregoing criteria without requirement for arginine as a stabilizer.
  • the stabilizer is calcium chloride
  • the calcium chlonde is present in an amount not exceeding about 5 mM calcium chloride and the composition further comprises: optionally about 0.5 to 6 wt.% sucrose or trehalose; optionally about 0 to 100 mM NaCI; optionally up to about 10 mM xylitol; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 8.0 to 6.6; and wherein, optionally, the composition contains no arginine or is essentially free of arginine.
  • the calcium chloride stabilized composition comprises about 50 mg/ml of etanercept; about 2 mM calcium chloride; about 10-30 mM sodium phosphate; less than about 150 mM sodium chloride; and less than about 4 wt.% sucrose; wherein the formulation has a pH of about 6.3 to 6.5.
  • the calcium chloride stabilized composition comprises about 50 mg/ml of etanercept; about 2 mM calcium chloride; about 0-30 mM sodium phosphate; less than about 10 wt.% sucrose; wherein the formulation has a pH of about 6.3 to 6.5.
  • the calcium chloride stabilized composition comprises about 50 mg/ml of etanercept; about 2 mM calcium chloride; about 10-30 mM sodium phosphate; less than about 100 mM sodium chloride; and less than about 5 wt.% sucrose; wherein the formulation has a pH of about 6.3 to 6.5.
  • the calcium chloride stabilized composition comprises about 50 mg/ml of etanercept; about 1 mM calcium chloride; about 10-30 mM sodium phosphate; about 50 mM sodium chloride; and less tha about 8 wt.% trehalose; wherein the formulation has a pH of about 6.3 to 6.5.
  • the stabilized etanercept composition comprises about 1 mM to about 20 mM magnesium chloride; optionally up to about 6 wt.% sucrose; about 25 to 150 mM NaCI; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 6.0 to 6.6; and wherein, optionally, the composition contains no arginine or is essentially free of arginine.
  • the stabilized etanercept composition comprises about 50 mg/ml of etanercept; about 10 mM magnesium chloride; about 10-30 mM sodium phosphate; less than about 50 mM sodium chloride; and less than about 3 vvt.% sucrose; and having a pH of about 6.3 to 6.5.
  • the stabilized etanercept composition comprises about 50 mg/ml of etanercept; about 5 mM magnesium chloride; about 10-30 mM sodium phosphate; less than about 100 mM sodium chloride; and less than about 4 wt.% sucrose: and having a pH of about 6.3 to 6.5.
  • the stabilized etanercept composition comprises about 50 mg/ml of etanercept; about 4 mM magnesium chloride; about 10-30 mM sodium phosphate; about 100 mM sodium chloride; and about 2.5 wt.% sucrose; and having a pH of about 6.3 to 6.5.
  • the stabilized etanercept composition comprises about 50 mg/mi of etanercept; about 10 mM magnesium chloride; about 10-30 mM sodium phosphate; less than about 100 mM sodium chloride; and less than about 5 wt.% sucrose; and having a pH of about 6.3 to 6.5.
  • the etanercept compositions of the invention further afford the ability to provide formulations which contain acceptable levels of subvisible particles. Accordingly, the invention is further directed to metal ion stabilized etanercept formulations having, at M 3 or T ? . or T 4 , no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5pm.
  • the stabilized etanercept composition of the present invention are further characterized by: (a) an SEC analysis at M 3 or T 2 or T of greater than about 90 wt% monomer content; and less than about 3 wt% aggregate(s) content; and (b) an HSC analysis at M3 or T 2: or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than 80 wt%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 20 wt%, and wherein the formulation contains no arginine or is essentially free of arginine.
  • the stability of the formulations may be further characterized In that the compositions exhibit an HiC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 1%; the amount of the composition represented by peak 2 of the HiC chromatogram is greater than about 95 wt%; and the amount of the composition represented by peak 3 of the NIC chromatogram is less than about 3 wt%.
  • the etanercept formulation comprises about 50 mg/ml etanercept; 1 to 5 mlVI calcium chloride; about 1 to 30 mM sodium phosphate; about 0 to 100 m NaCI; about 0.5 to 5% sucrose or trehalose or combination thereof; and wherein the composition has a pH of about 8.0 to 8.6 and characterized by: an SEC analysis at M 3 or T 2 or T 4 of greater than about 97 wt.% monomer content and less than about 1 wt% aggregate(s) content; an HIC analysis at 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 4 wt%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 82 wt%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 15 wt%.
  • the stabilized etanercept composition comprises about 1 mM to about 20 mM magnesium chloride; optionally up to about 6 wt% sucrose; about 25 to 150 mM NaCI; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 6.0 to 6.6; and wherein the composition is characterized by: an SEC analysis at 3 or T 2 or T 4 of greater than about 97 wt.% monomer content and less than about 1 wt% aggregate(s) content; and an HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 4 wt%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 85 wt%; and the amount of the composition represented by peak 3 of the HfC chromatogram is less than about 14 wt%.
  • Formulations of the present invention utilizing magnesium ch!oride for
  • Preferred stabilized compositions of the invention exhibit an HIC analysis at K% or T 2 or T wherein the amount of the composition represented by peak 1 of the HSC chromatogram is less than about 2% and preferably less than about 1%; the amount of the composition represented by peak 2 of the HiC chromatogram is greater than about 95 wt% and preferably greater than about 97%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 3 wt%, and preferably 0 to 1%.
  • the invention provides a stabilized aqueous pharmaceutical composition
  • a stabilizer to inhibit instability, aggregation misfolding and/or fragmentation of the etanercept, wherein said stabilizer comprises a stabilizing metal ion.
  • the metal ion is selected from the group consisting of calcium, magnesium, zinc, and combinations thereof, in an even more preferred embodiment, caicium, magnesium, zinc are provided as caicium chloride, magnesium chloride and zinc chloride, respectively. Calcium chioride and magnesium chloride are particularly preferred as stabilizers for etanercept.
  • the term "instability" or like terms denotes the tendency of the etanercept monomer to undergo a variety of undesired transformations during storage. Such transformations include the formation of oligomers and high molecular weight aggregate(s) (hereinafter termed “aggregates") in which multiple copies of the essentially intact etanercept monomer become irreversibly associated with one another through a variety of non-covending attractions (e.g., electrostatic interactions.) Undesired transformations during storage may also include degradation of the etanercept monomer to smaller fragments and/or clipped species.
  • a formulaton of etanercept should minimize, to the greatest extent possible, the tendency of the formulation to result, during storage, in the formation of aggregates, misfolded protein, oligomers and/or fragments of the etanercept.
  • An important benefit resulting from the ability to reduce formation of unwanted aggregates or fragments is a reduction in the potential toxicity and/or immunogenicity of the drug.
  • the metal ion stabilized formulation is optionally and preferably free, or essentially free of arginine.
  • essentialtiaiiy free of arginine is intended to mean that arginine, even if present, is not contributing to the stabilization of the etanercept monomer in the formulation to such an extent that a person skilled in the art would judge its presence beneficial or necessary from a stabilization standpoint.
  • etanercept or "etanercept monomer” or “monomer” is synonymous with Enbrel®. It refers to a polypeptide which is a dimeric fusion polypeptide consisting of the extracellular .ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human igG1. It consists of 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons.
  • etanercept also encompasses etanercept with minor modifications in the amino acid structure (including deletions, additions, and/or substitutions of amino acids) which do not significantly affect the function, potency, or avidity of etanercept.
  • etanercept encompasses all forms and formulations of Enbre!®, including but not limited to concentrated formulations, injectable ready-to-use formulations; formulations reconstituted with water, alcohol, and/or other ingredients, and others.
  • the term “monomer” as used herein is intended to mean the dimer c etanercept fusion protein referenced above.
  • sugar refers to monosaccharides, disaccharides, and polysaccharides.
  • sugars include, but are not limited to, sucrose, trehalose, dextrose, and others.
  • metal ion refers to a metal atom with a net positive or negative electric charge.
  • metal ion also includes sources of metal ions, including but not limited to metal salts.
  • long-term storage is understood to mean that the pharmaceutical composition can be stored for three months or more, for six months or more, and preferably for one year or more. Long-term storage is also understood to mean that the pharmaceutical composition is stored either as a liquid at 2-8° C, or is frozen, e.g., at -2G°C, or colder. It is also contemplated that the composition can be frozen and thawed more than once.
  • stable or “stabilized” with respect to long-term storage is understood to mean that etanercept contained in the pharmaceutical compositions does not lose more than 20%, or more preferably 15%, or even more preferably 10%, and most preferably 5% of its activity relative to activity of the compositio at the beginning of storage,
  • mammal includes, but is not limited to, a human.
  • pharmaceutically acceptable carrier refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material, formulation auxiliary, or excipient of any conventional type.
  • a pharmaceutically acceptable carrier is nontoxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • composition refers to a mixture that usually contains a carrier, such as a pharmaceutically acceptable carrier or excipient that is conventional in the art and which is suitable for administration into a subject for therapeutic, diagnostic, or prophylactic purposes. It may include a cell culture in which the polypeptide or polynucleotide is present in the cells or in the culture medium.
  • a carrier such as a pharmaceutically acceptable carrier or excipient that is conventional in the art and which is suitable for administration into a subject for therapeutic, diagnostic, or prophylactic purposes. It may include a cell culture in which the polypeptide or polynucleotide is present in the cells or in the culture medium.
  • compositions for oral administration can form solutions, suspensions, tablets, pills, capsules, sustained release formulations, oral rinses or powders.
  • pharmaceutical composition and “formulation” are used interchangeably.
  • treatment refers to any administration or application of remedies for disease in a mammal and includes inhibiting the disease, arresting its development, relieving the disease, for example, by causing regression, or restoring or repairing a lost, missing, or defective function; or stimulating an inefficient process.
  • the term includes obtaining a desired pharmacologic and/or physiologic effect, covering any treatment of a pathological condition or disorder in a mammal.
  • the effect may be prophylactic in terms of completely or partially preventing a disorder or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disorder and/or adverse affect attributable to the disorder.
  • It includes (1) preventing the disorder from occurring or recurring in a subject who may be predisposed to the disorder but is not yet symptomatic, (2) inhibiting the disorder, such as arresting its development, (3) stopping or terminating the disorder or at least its associated symptoms, so that the host no longer suffers from the disorder or its symptoms, such as causing regression of the disorder or its symptoms, for example, by restoring or repairing a lost, missing or defective function, or stimulating an inefficient process, or (4) relieving, alleviating or ameliorating the disorder, or symptoms associated therewith, where ameliorating is used in a broad sense to refer to at least a reductio in the magnitude of a parameter, such as inflammation, pain and/or tumor size.
  • disease refers to any condition, infection, disorder or syndrome that requires medical intervention or for which medical intervention is desirable, Such medical intervention can include treatment, diagnosis and/or prevention.
  • an effective amount of the polypeptide of the invention for administration to the living subject is an amount that prevents and/or treats an integrin avpS-mediated disease.
  • the exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for systemic versus localized delivery, age, bod weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those ski!led in the art.
  • Tn refers to a point in time, at which an etanercept formulation has been stored for about one week at 40° C
  • T 2 refers to a point in time at which an etanercept formulation has been stored for about two weeks at 40° C
  • T 4 refers to a point in time at which an etanercept formulation has been stored for about four weeks at 40° C.
  • 3 refers, collectively, to three points in time, and in particular to an analytical result being observed for an etanercept formulation after duration of either about one, about two or about three months of storage at a storage temperature of 5° C.
  • reference herein to an analysis being conducted at M3 should be understand to mean that such analysis is be done at the point in time at which etanercept formulation has been in storage for a duration selected from about one, about two, or about three months.
  • an etanercept formulation elicit a certain analytical value or measurement at 3 is satisfied if the required value is observed at a point in time corresponding to at least one of the following storage durations; at approximately one month, at approximately two months or at approximately three months of storage at 5°C.
  • Peak 1 Peak 2
  • Peak 3 Peak 3 when used herein in connection with discussion of HIC chromatography results refers to the same peaks 1, 2 and 3 discussed in US Patent 7,294,481.
  • etanercept When pharmaceutical compositions containing etanercept (Enbrel®), including aqueous and lyophilized formulations of etanercept are stored on a long term basis, the activity of etanercept can be lost or decreased due to instability of the etanercept monomer via aggregation and/or chemical degradation including formation of fragments.
  • the present invention provides several embodiments of aqueous formulations of etanercept that allow stable long-term storage of etanercept, so that etanercept is stable over the course of storage either in liquid or frozen states.
  • the provided formuiaiions include, but are not iimsted to formulations that do not contain arginine and do not require any extra steps such as rehydrating.
  • AH of the compositions of the present invention comprise etanercept (Enbre!®).
  • etanercept is a dimeric fusion polypeptide consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human lgG1.
  • TNFR tumor necrosis factor receptor
  • Etanercept consists of 934 amino acids.
  • the Fc component of etanercept contains the constant heavy 2 (CH2) domain, the constant heavy 3 (CH3) domain and hinge region of human IgGI .
  • An Fc domain can contain one or all of the domains described above.
  • Etanercept suitable for storage in the present pharmaceutical composition can be produced by living host cells that express etanercept, such as hybridomas in the case of antibodies, or host cells that that have been genetically engineered to produce the polypeptide in the case of fusion polypeptides or antibodies.
  • Methods of genetically engineering cells to produce polypeptides are well known in the art. See, e.g., Ausubel et al., eds. (1990), Current Protocols in Molecular Biology (Wiley, New York). Such methods include introducing nucleic acids that encode and allow expression of the polypeptide into living host cells.
  • These host cells can be bacterial cells, fungal cells, or, preferably, animal cells grown in culture.
  • Bacterial host cells include, but are not limited to, Escherichia coli cells.
  • suitable £. coli strains include: ⁇ 810 ⁇ , DHS.alpha, GM2929, JM109, KW251 , NM538, N 539, and any E. cols strain that faiis to cleave foreign DNA.
  • Fungal host ceils that can be used include, but are not limited to, Saccharomyces cerevisiae, Pichia pastoris and Aspergillus cells.
  • a few examples of animal cell lines that can be used are CHO, VERO, BHK, HeLa, Cos, MDCK, 293, 3T3, and W138.
  • New animal cell lines can be established using methods well know by those skilled in the art (e.g., by transformation, viral infection, and/or selection).
  • etanercept can be secreted by the host cells into the medium. Purification of the expressed etanercept can be performed by any standard method. When etanercept is produced intraceliularly, the particulate debris is removed, for example, by centrifugation or ultrafiltration. When etanercept is secreted into the medium, supernatants from such expression systems can be first concentrated using standard polypeptide concentration filters. Protease inhibitors can also be added to inhibit proteolysis and antibiotics can be included to prevent the growth of microorganisms.
  • Etanercept can be purified using, for example, hydroxyapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography, and any combination of known or yet to be discovered purification techniques, including but not limited to Protein A chromatography, fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSET®, an anion or cation exchange resin chromatography (such as a polyaspartie acid column), chromatofocusing, SDS- PAGE, and ammonium sulfate precipitation.
  • Protein A chromatography fractionation on an ion-exchange column, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSET®, an anion or cation exchange resin chromatography (such as a polyaspartie acid column), chromatofocusing, SDS- PAGE, and ammonium sulfate precipit
  • the invention provides a stabilized aqueous pharmaceutical composition
  • a stabilized aqueous pharmaceutical composition comprising etanercept and a stabilizer to inhibit instability, aggregation and/or fragmentation of the etanercept, wherein the stabilizer comprises a stabilizing metal ion.
  • metal ions such as calcium, magnesium, and zinc act as conformational stabilizers to reduce etanercept's tendency to aggregate. The reduction in aggregation is believed to last for a long period of time, e.g., two years or more.
  • metal ions are able to stabilize aqueous pharmaceutical compositions containing etanercept because the metal can bind to the native state, where the right geometry of ligands occurs, !n doing so, there is a net stabilization of the native state. Once the protein unfolds, the binding site is lost, and the denatured state in relatively unaffected in terms of free energy.
  • metal biding may also improve the colloidal stability of the protein, eiading to decreased aggregation and increased solubility.
  • the stabilization effects of metal ion are may not be limited to reduction in aggregates but may also address other aspects of instabiiity of the etanercept monomer in the formulation.
  • the metal ion is selected from the group consisting of calcium, magnesium, zinc, and combinations thereof, in an even more preferred embodiment, calcium, magnesium, and zinc are provided as calcium chloride, magnesium chloride and zinc chloride, respectively.
  • the pharmaceutical compositions of the invention may be prepared by combining, a purified etanercept and a metal son. Further, a buffer, a tonicity modifier and an additional excipieni and other commonly used inactive ingredients can be added as needed. For simplicity, these are discussed more fully later in the specification. A person of ordinary skill in the art will understand that the combining of the various components to be included in the composition can be done in any appropriate order. For example, the buffer can be added first, middle or last, and the tonicity modifier can also be added first, middle or last. A person of ordinary skill in the art will also understand that some of these chemicals can be incompatible in certain combinations, and accordingly, are easily substituted with different chemicals that have similar properties but are compatible in the relevant mixture.
  • the concentration of the metal ion in the provided formulations is preferably between about 1 mM to 0.5 M, more preferably about 1 m to about 100 mM, more preferably about 2 mM to about 20 mM, and yet more preferably about 2 to 10 mM.
  • Sources of metal ions are available from commercial suppliers.
  • an etanercept formulation of the invention comprises about 25 to about 50 mg/ml of etanercept; up to about 5 mM calcium chloride; optionally about 0.5 to 6 wt.% sucrose or trehalose; optionally about 0 to100 mM NaCI; optionally up to about 10 mM xylitol; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 6.0 to about pH 7.0, and more preferably about 6.0 to about 6.6 and most preferably about 6.3 to about 6,5.
  • an etanercept formulation of the invention can comprise about 25 to about 50 mg/ml of etanercept; about 1 mi to about 20 mM magnesium chioride; optionally up to about 6 wt.% sucrose; about 25 to 150 m NaCI; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 6.0 to about pH 7.0, and more preferably about 6.0 to about 6.6 and most preferably about 6.3 to about 6.5.
  • Compositions stabilized with metal ions are preferably characterized as having an SEC analysis at T 2 of; about 80 wt.% to about 95 wt.% monomer content; an SEC analysis at T 2 of aggregate(s) content of less than about 4 wt.%; and an SEC analysis at T 2 of fragment 3 content of less than about 8 wt.%.
  • etanercept formulations containing a stabilizing metal ion according to the invention elicit stability characterized by;
  • the etanercept formulations of the present invention containing metal ion for stabilization are more preferably characterized by having an HiC analysis at T 4 or T 2 wherein the amount of the composition represented by peak 1 of the HiC chromatogram is less than about 1%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 95 wt% and most preferably greater than about 99 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 3 wt.%.
  • Preferred etanercept formulations stabilized with calcium chloride comprise; about 50 mg/ml etanercept; 1 to 5 mM calcium chloride; about 1 to 30 mi sodium phosphate; about 0 to 100 mM NaCI; about 0.5 to 5% sucrose or trehalose or combination thereof; and wherein the composition has a H of about 6.0 to 6,6 and characterized by: an SEC analysis at T 4 of greater than about 97 wt.% monomer content and less than about 1 wt>% aggregate(s) content; an H!C analysis at T 2 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 4 wt.%; the amount of the composition represented by peak 2 of the HIC chromatogram is greater than about 82 wt.%; and the amount of the composition represented by peak 3 of the HSC chromatogram is less than about 15 wt.%; and an HIC analysis at T 4 wherein the amount of the composition represented by peak 1 of the HIC
  • Preferred etanercept formulations stabilized with magnesium chloride comprise: about 1 mM to about 20 mM magnesium chloride; optionally u to about 6 wt.% sucrose; about 25 to 150 mM NaCI; about 1 to about 30 mM sodium phosphate; wherein the composition has a pH of about 6.0 to 6.6; and wherein the composition is characterized by: an SEC analysis at T 4 of greater than about 97 wt.% monomer content and less than about 1 wt.% aggregate(s) content; an HIC analysis at T 2 wherein the amount of the composition represented by peak 1 of the HiC chromatogram is less than about 4 wt.%; the amount of the composition represented by peak 2 of the HiC chromatogram is greater than about 85 wt.%; and the amount of the composition represented by peak 3 of the HIC chromatogram is less than about 14 wt.%; and an HIC analysis at T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than
  • a stabiiized etanercept formuiation having the analytical properties referenced above comprises: about 50 mg/m! of etanercept; about 2 m calcium chioride; about 15 mM sodium phosphate; about 75 mM sodium chioride; and about 3 wt.% sucrose; wherein the formulation has a pH of about 6.3 to 6.5.
  • the metal ion stabilized etanercept composition the stabilizer is calcium chloride or magnesium chioride, the formulation is free or essentially free of arginine, and the formulation elicits long term storage stability as characterized by:
  • the stabilizer is calcium chloride and/or magnesium chloride, and the stabilized composition elicits long term storage stability as characterized by:
  • properties referenced above comprises: about 50 mg/ml of etanercept; about 10 m magnesium chloride; about 15 mM sodium phosphate; about 75 rn sodium chloride; and about 3 wt.% sucrose; and having a pH of about 6.3 to 6,5,
  • a calcium chloride or magnesium chloride stabilized etanercept composition according to the invention elicits long term storage stability as characterized by: an HIC analysis at M 3 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equai to about 95 wt.%; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 1 wt.%.
  • the metal son stabilized etanercept formulations containing no arginine, are found to elicit stability over three months storage at 5C that is comparable to or better than the presently available arginine containing formulation of commercially available Enbrel. Accordingly the present invention is further directed to metal ion stabilized formulations of etanercept, which contain no arginine, or are essentially free of arginine, and wherein the composition, after storage at 5° C for one, two or three months, elicits long term storage stability that meets one or both of the following criteria when evaluated at a point in time selected from one or more of the following: at approximately one month, at approximately two months or at approximately three months after initiation of storage of the composition at a storage temperature of 5° C:
  • the etanercepf formulations comprising metal ion for stabilization according to the present invention are preferably free or essentially free of arginine.
  • the formulations of the invention may also include buffers, tonicity modifiers, excipients, pharmaceutically acceptable carriers and other commonly used inactive ingredients of the pharmaceutical compositions. For simplicity, these are discussed more fully later in the application.
  • Buffers maintain pH in a desired range.
  • Suitable buffers include histidine, potassium phosphate, sodium or potassium citrate, maieic acid, ammonium acetate, tris-(hydroxymethyl)-amsnomethane (tris), various forms of acetate and diethanolamine.
  • concentration of the buffer in the formulation is preferably between about 1 m to about 1.M, and more preferably about 10 mM to about 200 mM. Buffers are well known in the art and are manufactured by known methods and available from commercial suppliers.
  • buffers examples include phosphate, histidine, citrate, maleate, tartrate, succinate, acetate, tris-(hydroxymethyl)-am.inomethane (tris), bicarbonate.
  • the buffer is sodium phosphate.
  • the pH of the pharmaceutical composition is at or near physiological levels.
  • the pH of the provided compositions is between about 5.8 and about 8.4; and even more preferably, between about 6.2 and about 7.4.
  • the pH can be adjusted as necessary to maximize stability and solubility of etanercept in a particular formulation.
  • etanercept formulations at a pH outside of physiological ranges, yet tolerable to the patient, are also within the scope of the invention.
  • a tonicity modifier is a molecule that contributes to the osmolality of a solution.
  • the osmolality of a pharmaceutical composition is preferably adjusted to maximize the active ingredient's stability and/or to minimize discomfort to the patient upon administration. It is generally preferred that a pharmaceutical composition be isotonic with serum, i.e., having the same or similar osmolality, which is achieved by addition of a tonicity modifier.
  • the osmolality of the provided formulations is from about 180 to about 420 mOsM.
  • the osmolality can be either higher or lower as specific conditions require.
  • tonicity modifiers suitable for modifying osmolality include, but are not limited to amino acids (not including arginine) (e.g., cysteine, histidine and glycine), salts (e.g., sodium chloride, potassium chloride and sodium citrate) and/or saccharides (e.g., sucrose, glucose and mannitol).
  • amino acids not including arginine
  • cysteine e.g., cysteine, histidine and glycine
  • salts e.g., sodium chloride, potassium chloride and sodium citrate
  • saccharides e.g., sucrose, glucose and mannitol
  • Preferred tonicity modifiers are glycine, alanine, sodium chloride, potassium chloride, and sodium sulfate.
  • the concentration of the tonicity modifier in the formulation i preferably between about 1 mM to about 1 M, more preferably about 10 mM to about 200 mM.
  • concentration of the tonicity modifier in the formulation i preferably between about 1 mM to about 1 M, more preferably about 10 mM to about 200 mM.
  • Tonicity modifiers are well known in the art and are manufactured by known methods and available from commercial suppliers.
  • Excipients also referred to as chemical additives, co-solutes, or co-solvents, that stabilize the polypeptide while in solution (also in dried or frozen forms) can also be added to a pharmaceutical composition.
  • Excipients are well known i the art and are manufactured by known methods and available from commercial suppliers.
  • excipients include but are not limited to sugars/polyo!s such as: sucrose, lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, trehalose, glucose; polymers such as: serum albumin (bovine serum albumin (BSA), human SA or recombinant HA), dextran, poiy(viny alcohol) PVA, hydrcxypropy!
  • sugars/polyo!s such as: sucrose, lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, trehalose, glucose
  • polymers such as: serum albumin (bovine serum albumin (BSA), human SA or recombinant HA), dextran, poiy(viny alcohol) PVA, hydrcxypropy!
  • methylcellulose HPMC
  • polyethyleneimine gelatin
  • polyvinylpyrrolidone PVP
  • hydroxyethylcellulose HEC
  • non-aqueous solvents such as: poiyhydric alcohols, (e.g., PEG, and glycerol) and dimethyiformamide (DMF); amino acids such as: proline, L-serine, sodium glutamic acid, alanine, glycine, lysine hydrochloride, sarcossne and gamma-aminobutyriG acid; surfactants such as: Tween®-80 (polysorbate 80), Tween ⁇ -20 (polysorbate 20), SDS, polysorbate, poloxamers; and miscellaneous excipients such as: potassium phosphate, sodium acetate, ammonium sulfate, magnesium sulfate, sodium sulfate, trimethylamine N-oxide, betaine, metal ions (e.g
  • Preferred excipients are sucrose, lactose, glycerol, xylitol, sorbitol, mannitol, maltose, inositol, trehalose, glucose, bovine serum albumin (B ' SA), human serum albumin (HSA), recombinant albumin, dextran, PVA, hydroxypropyl methylcellulose (HP CJ, poiyethyieneimine, gelatin, polyvinylpyrrolidone (PVP), hydroxyethylceiluiose (HEC), polyethylene glycol, ethylene glycol, glycerol, alanine, glycine, lysine hydrochloride, sarcossne, SDS, polysorbate 20, polysorbate 80, poloxamer 188, trimethylamine N-oxide, betaine, zinc ions, calcium ions, magnesium ions, CHAPS, sucrose monolaurate, and 2-0-beta-manno
  • concentration of one or more excipients in a formulation of the invention is/are preferably between about 0.001 to 5 weight percent, more preferably about 0.1 to 2 weight percent.
  • the invention provides a method of treating a mammai comprising administering a therapeutically effective amount of the pharmaceutical compositions of the invention to a mammal, wherein the mammal has a disease or disorder that can be beneficially treated with etanercept.
  • the etanercept is derived from the same species of mammai as is to be treated with the composition.
  • the mammal is a human.
  • Diseases or disorders that can be treated with the provided compositions include but are not limited to rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Wegener's disease (granulomatosis), Crohn's disease (or inflammatory bowel disease), chronic obstructive pulmonary disease (COPD), Hepatitis C, endometriosis, asthma, cachexia, psoriasis, and atopic dermatitis.
  • Additional diseases or disorders that can be treated with the compositions of the present invention include those described in WO 00/62790, WO 01/62272, U.S. Patent Application No. 2001/0021380, and US Pat. 7,648.702 B2, the relevant portions of which are incorporated herein by reference.
  • compositions may be administered to a subject in need of treatment by injection systemical!y, such as by intravenous injection; or by injection or application to the relevant site, such as by direct injection, or direct application to the site when the site is exposed in surgery; or by topical application.
  • injection systemical!y such as by intravenous injection
  • injection or application to the relevant site such as by direct injection, or direct application to the site when the site is exposed in surgery; or by topical application.
  • the invention provides a method of treatment and/o prevention of rheumatoid arthritis comprises administering to a mammal in need thereof a therapeutically effective amount of one of the provided etanercept compositions.
  • the therapeutically effective amount of the etanercept in the provided compositions will depend on the condition to be treated, the severity of the condition, prior therapy, and the patient's clinical history and response to the therapeutic agent.
  • the proper dose can be adjusted according to the judgment of the attending physician such that it can be administered to the patient one time or over a series of administrations.
  • the effective etanercept amount per adult dose is from about 1-500 mg/m 2 , or from about 1-200 mg/m 2 , or from about 1-40 mg/m 2 or about 5-25 mg/m 2 .
  • a flat dose may be administered, whose amount may range from 2-500 mg/dose, 2-100 mg/dose or from about 10-80 mg/dose.
  • an exemplary dose range is the same as the foregoing described dose ranges or lower and preferably administered two or more times per week at a per dose range of 25-100 mg/dose.
  • an acceptable dose for administration by injection contains 80-100 mg/dose, or alternatively, containing 80 mg per dose.
  • the dose can be administered weekly, biweekly, or separated by several weeks (for example 2 to 8).
  • etanercept is administered at 25 to 75 mg/m! by a single subcutaneous (SC) injection.
  • SC single subcutaneous
  • an improvement in a patient's condition will be obtained by administering a dose of up to about 100 mg of the pharmaceutical composition one to three times per week over a period of at least three weeks. Treatment for longer periods may be necessary to induce the desired degree of improvement. For incurable chronic conditions the regimen may be continued indefinitely. For pediatric patients (ages 4-17), a suitable regimen may involve administering a dose of 0.4 mg/kg to 5 mg/kg of etanercept, one or more times per week.
  • the pharmaceutical formulations of the invention may be prepared in a bulk formulation, and as such, the components of the pharmaceutical composition are adjusted to be higher than would be required for administration and diluted appropriately prior to administration.
  • the pharmaceutical compositions can be administered as a sole therapeutic or in combination with additional therapies as needed.
  • the provided methods of treatment and/or prevention are used in combination with administering a therapeutically effective amount of another active agent.
  • the other active agent may be administered before, during, or after administering the pharmaceutical compositions of the present invention.
  • Another active agent may be administered either as a part of the provided compositions, or alternatively, as a separate formulation.
  • Administration of the provided pharmaceutical compositions can be achieved in various ways, including parenteral, peroral, buccal, sublingual, nasal, rectal, intraperitoneal, intradermal, transdermal, subcutaneous, intravenous, intra-arterial, intracardiac, intraventricular, intracranial, intratracheal, intrathecal administration, intramuscular injection, intravitreal injection, and topical application.
  • compositions of this invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly, intravenously, intraperitoneal, intracerebrospinai, i.ntra-articular, intrasynovial, intravitreal, and/or intrathecal.
  • Parenteral administration can be by bolus injection or continuous infusion.
  • Pharmaceutical compositions for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • compositions of the present invention are suitable for administration using these new methods, e.g., Inject-ease®, Genject®, injector pens such as GenPen®, and needleless devices such as MediJector® and BioJector®.
  • the present pharmaceutical composition can also be adapted for yet to be discovered administration methods. See also Langer, 1990, Science, 249:1527-1533,
  • compositions can also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the formulations may be modified with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or son exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions may, if desired, be presented in a vial, pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the dispenser device can comprise a syringe having a single dose of the liquid formulation ready fo injection.
  • the syringe can be accompanied by instructions for administration.
  • the present invention is directed to a kit or container, which contains an aqueous pharmaceutical composition of the invention.
  • concentration of the polypeptide in the aqueous pharmaceutical composition can vary over a wide range, but is generally within the range of from about 0.05 to about 20,000 micrograms per milliliter ( g/ml) of aqueous formulation.
  • the kit can also be accompanied by instructions for use.
  • Etanercept formulations may be prepared using the following procedures: Each solid formulation component Is weighed to the amount required for a given volume of formulation buffer. These components are combined into a beaker or vessel capable of carrying and measuring the given volume of formulation buffer. A volume of deionized water equal to approximately 3 ⁇ 4 of the target given formulation buffer is added to the beaker, and the components are then solublized. The pH of the buffer is adjusted to the target formulation pH using 1 M sodium hydroxide and/or 1 hydrogen chloride. The final formulation buffer volume is then raised to the target volume through the addition of deionized water.
  • Etanercept protein solution is placed in dialysis material housing (such as Thermo Scientific Slide-A-Lyzer MINI Dialysis Unit 10,000 WCO), which is then placed in contact with the desired formulation buffer for 12 hours at 4 C C.
  • Formulation buffer volume to protein solution volume ratio shouid be no less than 1000:1.
  • the dialysis housing and protein solution it contains is then placed in a second, equal volume of formulation buffer for an additional 12 hours at 4°C.
  • Resulting protein solution is removed from the dialysis material housing, and the concentration of protein determined using ultraviolet spectroscopy. Protein concentration is adjusted to the desired level using centrifugation (such as Amicon Ultra 10,000 MWCO Centrifugal Concentrators) and/or dilution with formulation buffer.
  • centrifugation such as Amicon Ultra 10,000 MWCO Centrifugal Concentrators
  • compositions can be tested for long-term stability by size exclusion chromatography (SEC), denatured SEC (dSEC), hydrophobic interaction chromatography (HIC), sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE), and for binding and bioactivity at various timepoints.
  • SEC size exclusion chromatography
  • dSEC denatured SEC
  • HIC hydrophobic interaction chromatography
  • SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis
  • composition will be stable over the term of two years or more.
  • Etanercept formulations stabilized with magnesium chloride may be prepared and tested using the procedures similar to those described in Example 1
  • the etanercept formulations exemplified be!ow do not contain arginine.
  • Etanercept formulations stabilized with zinc chloride may be prepared and tested using the procedures similar to those described in Example 1.
  • the etanercept formulation exemplified below does not contain arginine.
  • STEP 1 Ceil Expansion.
  • cell expansion necessary to generate a sufficient number of cells for inoculation of a production bsoreactor is performed using a clone of CHO ceils expressing the etanercept fusion protein.
  • the product of this expresson process results in a mixture of correctly folded etanercept, as well as incorrectly folded and/or aggregated etanercept, along with additional impurities.
  • the harvested cell culture fluid comprising such protein mixture is subjected to detergent viral inactivation,
  • Affinity Chromatography is performed on the harvested cell culture obtain in Step 1 above using a conventional Protein A affinity column in a well known manner. Product recovery is approximately 85%.
  • the product obtained is a complex protein mixture comprising correctly folded etanercept, incorrectly folded etanercept, and/or aggregates of correctly and/or incorrectly folded etanercept, or protein fragments.
  • the product obtained from this Protein A affinity column purification step is adjusted to pH 3.5 and then subjected to a viral inactivation step. Following viral inactivation the product is adjusted to pH 5.5 and then further clarified in a known manner using a commercially obtained capsule filter.
  • the Protein A pool from step 2 above is diluted to ⁇ 8 mS/cm with WFi and applied to a coiumn loading of up to 15 g/L media for each cycle.
  • the column is operated at a linear velocity of 200 cm/h to give a 6 minute residence time. After loading, the column is washed with 2 CV of 25 mM acetate pH 5.5.
  • the product is then eiuted with an 8.5 CV, 15% to 85% gradient of 25 mM acetate pH 5,5 to 25 mM acetate, 0.7 M NaCI, pH 5.5.
  • Product collection begins at 0.15 OD (A280, 1.0 cm path length) and collection ends at 50% of peak maximum.
  • the e!uate volume is approximately 5 CV. Residua!
  • STEP 3B Mixed Mode Anion Exchange Chromatopgraphy.
  • a 27.0 L (45 cm diameter X 17 cm bed height) packed bed GE Healthcare Capto Adhere chromatography column is used to further purify the product obtained in step 3A above.
  • the column Prior to use, the column Is equilibrated with 2 CV of 25 mM Tris, pH 8.0 and sanitized with 2 CV of 0.1 N NaOH, 1 M NaCl and neutralized and equilibrated with 2 CV of 25 m Tris, pH 8.0.
  • the Capto MMC pool from Step 3A above is adjusted to pH 8.1 with -0.045 kg of 1 M Tris, pH 8.3 per kg of pool.
  • the product from Step 3A above was diluted in-line 1 :3.8 with WFI to adjust the conductivity to 12.0 mS/cm and pH 8.0.
  • the resulting material is then applied to a column loading of up to 15 g/L media.
  • the column is operated at a linear velocity of 170 cm/b to give a 6 minute residence time. After loading, the column is washed with 2 CV of 25 mM Tris, pH 8.0.
  • the product is then eiuted with a 10 CV gradient (20% to 90%).
  • the final filtered product obtained in this example is found to have greater than about 90 wt % correctly folded etanercept as determined by HIC; iess than 5 wt% incorrectly folded etanercept species as determined by HIC; less than about 3 wt% of clipped material by HIC analysis (believed to be fragments of etanercept in which the TNFR portion thereof has been truncated) and a combined amount of correctly and incorrectly folded etanercept of greater than 95 wt% as determined by size exclusion chromatography.
  • Etanercept formulations disclosed herein were analyzed using the well known technique of Size Exclusion Chromatography (SEC), a high-performance liquid chromatography method in which anaiytes are separated by size (see Rogner, M. (2000). Size Exclusion Chromatography. Protein Liquid Chromatography. . Kastner. Amsterdam, Elsevier. 61 : 89-145.).
  • SEC Size Exclusion Chromatography
  • the samples were examined by a SEC method based on the literature (van aarschafkerweerd, A., G. J. Wolbink, et al. (2011).
  • the mobile phase buffer was prepared to contain 50 mM sodium phosphate monobasic rnonohydrate and 150 mM arginine. The pH was adjusted to 6.5 using 1 HCi. All separations were performed using a Tosoh TSK-Gel SvVxl 6 mm x 4 cm guard column (cat no. 8543) attached linearly to a Tosoh TSK-Gel G4000 SWxl 7.8 mm x 30 cm (cat. no. 8542).
  • the columns were brought to room temperature (23 0 C) and equilibrated with mobile phase at a flow rate of 0.5 mL/min. 5 microliters of 50 mg/mL etanercept formulation were injected onto the column using an autosampler. The separation was accomplished over 30 minutes at a flow rate of 0.5 mL/minute. Column e!uent was monitored at a wavelength of 280 nm during this time.
  • Ail integration was performed using Chromeleon software (Dionex), Prior to integration, the SEC chromatogram for a buffer containing no etanercept was subtracted from ail chromatograms. All integration was performed between retention times of 12 minutes and 26 minutes. Several parameters were used to define a peak. The minimum area for a detected peak was set to 0.05 mAu * min. The two- dimensional sensitivity for peak detection was set to 0.01 mAu and 75 seconds. Peak shoulders were added manually using a manual integration tool. All detected peaks were manually adjusted in two steps. First, peak baselines (the bottom boundary of the peak) were adjusted to horizontal. Secondly, the vertical positions of the peak baselines were adjusted to that of the chromatogram baseline. The chromatogram baseline value was defined as the signal in absence of analyte. The signal in absence of analyte was defined as the absorbance in mAu at 12 minutes retention time.
  • T 2 formulation stored for two weeks at 40 C
  • T 2 formulation stored for two weeks at 40 C
  • T 1 formuiation stored for one week at 40° C
  • T2 formulation stored for two weeks at 40 C
  • Table IV shows monomer (etanercept) content of etanercept formuiations prepared according to the present invention, when stored for four weeks at 25 C°- denoted by the symbol T 4 .
  • T 0 represents SEC measurements conducted within 24 hours of formulation preparation, at sample temperature of 5° C; and T 4 represents etanercept formulation samples subjected to SEC analysis after 4 weeks storage at 25° C.
  • Table V shows aggregate(s) content of etanercept formulations prepared according to the present invention after storage for four weeks at 25 C°, In the following tabie To represents SEC measurements conducted within 24 hours of formulation preparation, at sample temperature of 5° C; and T 4 represents etanercept formulation samples subjected to SEC analysis after 4 weeks storage at 25° C.
  • H1C chromatography hydrophobic interaction chromatography
  • Peak 1 in the HIC chromatogram is believed to be or include "Fragment 3", which is identified and quantified using SEC, as referenced above in the discussion of SEC data; Peak 2 is etanercept monomer as referenced above in the discussion of SEC data; and Peak 3 includes "Aggregate(s)” as referenced above in the discussion of SEC data.
  • Peak 1 peak 1 and peak 2 and peak 3 as used here also constitute a reference to the HIC peak 1, peak 2 and peak 3 referred to and disclosed in Figure 4 of U.S. patent 7,294,481 incorporated herein by reference.
  • Tables VIM through XV! contain the results of stability testing conducted on formulations 3:6 and 4:2 and containing etanercept material produced in the manner generally described Example 4 (Preparation of Etanercept), Stability of the formulations was evaluated using SEC, HIC and FlowCam analysis for subvisible particles, based on one, two and three months of storage at various temperatures, including 5°C. Following is the methodology used to conduct these stability experiments:
  • Non-formulated bulk etanercept was stored at 2 ⁇ 8°C as indicated by the Enb.rel® package insert.
  • UV Spectroscopy was used to determine protein concentration in various stability samples. The absorbance at 280 nm of bulk substance (50 mg/mL Enbrel) was determined to be 0.625 using a 0,1 mm pathiength cell, leading to an extinction coefficient of 1.30 mL/mg*cm, This value was used for ail calculations in this project.
  • Thermal Stability Sample Incubation. Following dialysis and concentration, thermal stability samples were sterile filtered in a bio safety cabinet. Using sterilized pipettes and aufoclaved pipette tips, samples were transferred to pre-labeled and autociaved 1 mL Iyophiiization vials. Viais were stoppered with steri!e butyi stoppers and crimped with aiuminum caps, Ali viais were then transferred to thermal stability ovens.
  • Size Exclusion Chromatography SEC was performed using different methods. In one of the SEC methods identified herein as "Method 2" the mobile phase buffer was prepared to contain 50 mM sodium phosphate monobasic monohydrate and 150 mM arginine HCI. The pH was adjusted to 6.5 using 1 M NaOH. Separations were performed using a Phenomonex Yarra 3 micron SEC 3000, 30cm x 4.6 mm. To perform a separation, the columns were brought to room temperature (23°C) and equilibrated with mobile phase at a flow rate of 0.5 ml/min.
  • Method 2 the mobile phase buffer was prepared to contain 50 mM sodium phosphate monobasic monohydrate and 150 mM arginine HCI. The pH was adjusted to 6.5 using 1 M NaOH. Separations were performed using a Phenomonex Yarra 3 micron SEC 3000, 30cm x 4.6 mm. To perform a separation, the columns were brought to room temperature (23°C) and
  • One microliter of 50 mg/mL etanercepi formulation were injected onto the column using an autosampler. The separation was accomplished over 10 minutes at a flow rate of 0.5 mL/minute. Column eluent was monitored at a wavelength of 280 nm during this time.
  • Method 3 NaCI NaCI was used as a salt for the mobile phase at a concentration of 100 mM, pH 6.3, in replacement of arginine HCI.
  • Method 1 the SEC analysis was conducted as follows: The mobile phase buffer was prepared to contain 50 mM sodium phosphate monobasic monohydrate and 150 mM arginine. The pH was adjusted to 6.5 using 1 M HCI. All separation were performed using a Tosoh TSK-Gel SVVxl 6 mm x 4 cm guard column (cat. no. 8543) attached linearly to a Tosoh TSK-Gel G4000 SWxl 7.8 mm x 30 cm (cat. no. 8542).
  • the columns were brought to room temperature (23° C) and equilibrated with mobile phase at a flow rate of 0.5 mL/mSn. 5 microliters of 50 mg/mL etanercept formulation were injected onto the column using an autosampler. The separation was accomplished over 30 minutes at a flow rate of 0.5 mL/minute. Column eluent was monitored at a wavelength of 280 nm during this time.
  • Ail integration was performed using Chromeieon software (Dionex). Prior to integration, the SEC chromatogram for a buffer containing no etanercept was subtracted from all chromatograms. Ail integration was performed between retention times of 2 minutes and 8 minutes. Several parameters were used to define a peak. The minimum area for a detected peak was set to 0.05 mAu * min. The two-dimensional sensitivity for peak detection was set to 0.01 mAu and 75 seconds. Peak shoulders were added manually using a manual integration tool. All detected peaks were manually adjusted 5 in two steps. First, peak baselines (the bottom boundary of the peak) were adjusted to horizontal.
  • the chromatogram baseline value was defined as the signal in absence of anaiyte. in this case, the signal in absence of analyte was defined as the absorbance in mAu at 2 minutes retention time.
  • HIC Hydrophobic interaction Chromatography
  • Solvent A 1.8 M ammonium sulfate, 0.1 . .sodium acetate pH 6.0 j
  • Solvent B 0.1 M sodium acetate pH 6.0 j
  • Method development work was performed on 7/10/12 initially using a Manuel Prime 20 with Non-Sample procedure (liquid to liquid interphase). Pronounced mixing effects were seen in the flow cell so an alternative air gap procedure (Manual Prime with Sample) was selected for sample evaluation.
  • the baseline (TO) formulations 3:8 and 4:2 samples were received frozen and had been stored at -20°C until thawed at ambient. Once thawed, the formulation was stored at refrigeration temperature (2-8°C).
  • the TtO sample method included a matching buffer pre-treatment ste to condition the flow ceil. Prior to loading the sample, 0.4 mL or more of the matching formulation buffer was flushed thru the system. It was determined that this pre-treatment was not required and was therefore not used for the t3 testing time point.
  • Samples of formulation 3:6 and 4:2 that had undergone three months of heat stress at 5° C and 25° C were evaluated in the FiowCAM analysis. All samples were thawed on the day they were analyzed. Once thawed, they were stored at refrigeration temperature (2-8° C).
  • FiowCAM Instrument Model VS1, Serial #551 with Sony SX90 camera and C70 pump with a 1 raL syringe (Fluid Imaging Technologies)
  • FiowCAM Software DSP Firmware Version: 54; version 3.0.3
  • Flow Cell Field of View (FOV FC80) with a depth of 80 ⁇ and a width of 700 ⁇ (Fluid Imaging Technologies)
  • System qualification included running water blanks and particle size standard i multiple replicates.
  • a cieaning procedure was undertaken to ensure particle counts were at acceptable levels typically below 1000 partic!es/mL between samples or less than 5% of the sample particies/mL between replicate samples.
  • the routine cleaning process used water (Miliipore Direct ⁇ Q type 1 , 0,22 ⁇ filtered, 18.2 ⁇ . ⁇ ) between cieaning agents and as a final flush prior to determining count levels. Once the particle count reached an acceptable particle per ml level the sample was carefully pipetted into the sample tip and loaded into the flow prior to initiating the sample analysis.
  • Run quality was determined during and immediately after each run using a series of diagnostic tools in VisuaiSpreadSheet including x-y capture plot (to visualize flow pattern dynamics), aspectic ratio to diameter size plot (identify stuck particles), image review during the run and image analysis at completion of run using various particle characteristics (e.g. size, circularity, length, aspect ratio).
  • diagnostic tools including x-y capture plot (to visualize flow pattern dynamics), aspectic ratio to diameter size plot (identify stuck particles), image review during the run and image analysis at completion of run using various particle characteristics (e.g. size, circularity, length, aspect ratio).
  • ESD Equivalent Spherical Diameter
  • Formulation 4:2 was evaluated for subvisible particles using the FiowCam flow imaging system. These instruments are designed to measure levels of subvisible particles (SVPs). These were measured initially (Table XIV) and then after three months at 5°C (Table XV) and 25°C (Table XVI). Consistent with the SEC and HIC data shown above indicating low levels of aggregate or misfoided material in formujation 4.2 after three month of thermal stress, formulation 4.2 exhibited low levels of subvisible particles (less than 10000 particles per rnL having a size greater than 5pm per m.L). TABLE XiV

Abstract

La présente invention concerne des compositions pharmaceutiques aqueuses stabilisées d'étanercept appropriées pour un stockage à long terme de l'étanercept, des procédés de fabrication de ces compositions, des méthodes d'administration, et des kits contenant lesdites formulations.
EP12842352.2A 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par des ions de magnésium Active EP2768525B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RSP20190864 RS59179B1 (sr) 2011-10-18 2012-10-18 Formulacije etanercepta stabilizovane jonima magnezijuma
SI201231635T SI2768525T1 (sl) 2011-10-18 2012-10-18 Formulacije etanercepta, stabilizirane z magnezijevimi ioni
PL12842352T PL2768525T3 (pl) 2011-10-18 2012-10-18 Preparaty etanerceptu stabilizowane jonami magnezu
HRP20191215TT HRP20191215T1 (hr) 2011-10-18 2019-07-04 Formulacije etanercepta stabilizirane ionima magnezija

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060739 WO2013059406A1 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par des ions métalliques

Publications (3)

Publication Number Publication Date
EP2768525A1 true EP2768525A1 (fr) 2014-08-27
EP2768525A4 EP2768525A4 (fr) 2015-07-15
EP2768525B1 EP2768525B1 (fr) 2019-06-19

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
EP12841765.6A Withdrawn EP2768533A4 (fr) 2011-10-18 2012-10-18 Préparations d'étanercept stabilisées avec des combinaisons de sucres et de polyols
EP12842226.8A Withdrawn EP2768854A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par des acides aminés
EP12841522.1A Withdrawn EP2768532A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par du chlorure de sodium
EP12841505.6A Withdrawn EP2768531A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par de la méglumine
EP12842312.6A Withdrawn EP2768535A4 (fr) 2011-10-18 2012-10-18 Préparations d'étanercept stabilisées avec du xylitol
EP12842352.2A Active EP2768525B1 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par des ions de magnésium

Family Applications Before (5)

Application Number Title Priority Date Filing Date
EP12841765.6A Withdrawn EP2768533A4 (fr) 2011-10-18 2012-10-18 Préparations d'étanercept stabilisées avec des combinaisons de sucres et de polyols
EP12842226.8A Withdrawn EP2768854A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par des acides aminés
EP12841522.1A Withdrawn EP2768532A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par du chlorure de sodium
EP12841505.6A Withdrawn EP2768531A4 (fr) 2011-10-18 2012-10-18 Formulations d'étanercept stabilisées par de la méglumine
EP12842312.6A Withdrawn EP2768535A4 (fr) 2011-10-18 2012-10-18 Préparations d'étanercept stabilisées avec du xylitol

Country Status (27)

Country Link
US (21) US9393305B2 (fr)
EP (6) EP2768533A4 (fr)
JP (6) JP6110393B2 (fr)
KR (7) KR20140091705A (fr)
CN (6) CN103998060B (fr)
AR (6) AR088460A1 (fr)
AU (6) AU2012326084B2 (fr)
BR (6) BR112014009131A8 (fr)
CA (6) CA2851642A1 (fr)
CY (1) CY1121843T1 (fr)
DK (1) DK2768525T3 (fr)
EA (6) EA026410B1 (fr)
ES (1) ES2734070T3 (fr)
HK (6) HK1200720A1 (fr)
HR (1) HRP20191215T1 (fr)
HU (1) HUE045624T2 (fr)
IL (6) IL231829A0 (fr)
IN (3) IN2014CN02527A (fr)
LT (1) LT2768525T (fr)
MX (7) MX2014004725A (fr)
PL (1) PL2768525T3 (fr)
PT (1) PT2768525T (fr)
RS (1) RS59179B1 (fr)
SG (6) SG11201401517VA (fr)
SI (1) SI2768525T1 (fr)
TW (6) TWI619504B (fr)
WO (6) WO2013059410A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2869817A1 (fr) * 2012-07-09 2015-05-13 Coherus Biosciences, Inc. Formulations aqueuses stables d'étanercept

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (fr) 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
US9393305B2 (en) * 2011-10-18 2016-07-19 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
WO2014043103A1 (fr) * 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Étanercept correctement replié de pureté élevée avec un excellent rendement
WO2014177548A1 (fr) * 2013-05-02 2014-11-06 Mabxience, S.A. Variantes de formulations de polypeptides de fusion tnrf:fc
WO2015056613A1 (fr) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Préparation aqueuse de polypeptide stabilisée
CN105611938A (zh) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
KR101712245B1 (ko) 2013-11-29 2017-03-06 아레스 트레이딩 에스.에이. TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
WO2015196091A1 (fr) 2014-06-20 2015-12-23 Reform Biologics, Llc Composés excipient réduisant la viscosité pour formulations à base de protéines
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
WO2016102328A1 (fr) * 2014-12-22 2016-06-30 Ares Trading S.A. Composition pharmaceutique liquide
US20180256717A1 (en) * 2014-12-23 2018-09-13 Drug Discovery Laboratory As Protein compositions and use thereof
BR112017014224A2 (pt) 2014-12-31 2018-03-06 Lg Chem, Ltd. método para a preparação de proteína de fusão fc-tnfr que contém teor alvo de impurezas
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX2015010517A (es) * 2015-08-13 2017-02-13 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
JPWO2017179683A1 (ja) * 2016-04-15 2019-02-21 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
WO2018075818A1 (fr) * 2016-10-21 2018-04-26 Amgen Inc. Formulations pharmaceutiques et leurs procédés de préparation
EP3533441A4 (fr) * 2016-10-28 2019-12-04 Celltrion Inc. Formulation pharmaceutique stable
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
EP3718531A4 (fr) * 2017-11-30 2023-08-16 Bio-Thera Solutions, Ltd. Préparation liquide d'anticorps humanisé pour le traitement d'une maladie liée à l'il-6
KR102494021B1 (ko) * 2017-12-22 2023-02-06 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
CA3042126A1 (fr) 2018-05-03 2019-11-03 Michael A. Portman Methodes de traitement de la maladie de kawasaki
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) * 2019-08-09 2019-09-25 Arecor Ltd Novel composition
JP2023502777A (ja) * 2019-11-26 2023-01-25 コメラ ライフ サイエンシズ，インコーポレイテッド バイオポリマー製剤のための賦形剤化合物
KR20230146579A (ko) 2021-02-17 2023-10-19 아레콜 리미티드 Fc 도메인을 포함하는 조작된 단백질 작제물의 수성 조성물
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072060A2 (fr) * 2002-02-27 2003-09-04 Immunex Corporation Preparation de polypeptides
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
WO2011141926A2 (fr) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited PRÉPARATION LIQUIDE DE POLYPEPTIDES CONTENANT UN DOMAINE Fc D'UNE IMMUNOGLOBULINE
WO2012143418A1 (fr) * 2011-04-20 2012-10-26 Sandoz Ag Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
WO2013006454A1 (fr) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Compositions de polypeptide de fusion tnfr:fc exempt d'arginine et leurs procédés d'utilisation

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
WO1994006476A1 (fr) 1992-09-15 1994-03-31 Immunex Corporation Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (fr) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
WO2000062790A2 (fr) 1999-04-19 2000-10-26 Immunex Corporation Traitement de troubles d'ordre medical par un recepteur de facteur de necrose tumorale soluble
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
EP2311492B1 (fr) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Préparations stabilisées contentant und anticorps
WO2003102013A2 (fr) * 2001-02-23 2003-12-11 Gonzalez-Villasenor Lucia Iren Procedes et compositions de production de peptides recombinants
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
JPWO2004082715A1 (ja) 2003-03-20 2006-06-22 エーザイ株式会社 炎症性腸疾患治療剤としての併用医薬
NZ545221A (en) 2003-08-01 2009-09-25 Amgen Inc Crystalline tumor necrosis factor receptor 2 polypeptides
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
WO2005082377A1 (fr) 2004-03-01 2005-09-09 Ajinomoto Co., Inc. INHIBITEUR POUR ABAISSER L’ACTIVITÉ DE L’ANTICORPS ANTIHUMAIN TNF-α
CN104593277A (zh) 2004-03-05 2015-05-06 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
WO2006138181A2 (fr) * 2005-06-14 2006-12-28 Amgen Inc. Preparations de proteines a tamponnage spontane
TW200738261A (en) * 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
EP1962907A2 (fr) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Formulations de proteines a viscosite reduite et leurs utilisations
EP1988922A4 (fr) 2006-02-03 2010-06-02 Medimmune Llc Formulations de protéines
SG170750A1 (en) * 2006-03-17 2011-05-30 Biogen Idec Inc Stabilized polypeptide compositions
EP1996076A2 (fr) 2006-03-21 2008-12-03 Eugen Oetringer Dispositifs et procédés d'analyse d'une condition physiologique d'un sujet physiologique basée sur une propriété associée de charge de travail
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
PE20081179A1 (es) * 2006-10-06 2008-09-29 Amgen Inc Formulaciones estables de anticuerpos egfr
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
ES2541546T3 (es) 2006-11-03 2015-07-21 Wyeth Llc Sustancias que inhiben la glucólisis en cultivo celular
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
EP2014760A1 (fr) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S Méthode pour produire un biopolymère (e.g. un polypeptide) pendant un procédé de fermentation continue
AU2008266051B2 (en) 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
NZ585702A (en) 2007-11-30 2013-08-30 Abbott Lab Protein formulations and methods of making same
RU2537139C2 (ru) * 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
EA201070987A1 (ru) 2008-02-29 2011-04-29 Байоджен Айдек Ма Инк. Очищенные гибридные белки иммуноглобулина и способы их очищения
WO2011015926A1 (fr) 2009-08-03 2011-02-10 Avesthagen Limited Procédé de fermentation, de purification et de production d’une protéine hybride soluble de recombinaison du récepteur du facteur de nécrose tumorale alpha (tnfr) - domaine fc de l’igg humaine
LT2464725T (lt) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
EP2490780A4 (fr) 2009-10-20 2014-04-09 Merck Sharp & Dohme Utilisation de la chromatographie en mode mixte pour la capture et la purification de produits d'anticorps de base
EP2516467A2 (fr) * 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprenant des antagonistes de tnf-alpha et il-6 et leurs procédés d'utilisation
MX2012012526A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo celular mejorado.
EP2598167B1 (fr) * 2010-07-30 2015-04-01 Arecor Limited Compositions aqueuses stabilisées d'anticorps
EP2606119A1 (fr) 2010-08-20 2013-06-26 Wyeth LLC Culture cellulaire de cellules adaptées exemptes de facteur de croissance
EP2611904A2 (fr) 2010-08-31 2013-07-10 Friesland Brands B.V. Milieu de culture pour cellules eucaryotes
BR112013008738B1 (pt) 2010-10-11 2017-12-19 Abbvie Bahamas Ltd. Method for purification of a protein
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013003731A2 (fr) 2011-06-29 2013-01-03 Insite Vision Incorporated Méthodes permettant de traiter un dysfonctionnement récurrent des glandes de meibomius et de réduire la fréquence de récurrence
AU2012279230B2 (en) 2011-07-01 2016-08-18 Amgen Inc. Mammalian cell culture
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
AU2012282960A1 (en) 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
JP6223338B2 (ja) 2011-08-17 2017-11-01 アレス トレーディング ソシエテ アノニム 活性型ＴＮＦＲ−Ｆｃ融合タンパク質を製造する方法
US9393305B2 (en) * 2011-10-18 2016-07-19 Coherus Biosciences, Inc. Etanercept formulations stabilized with xylitol
WO2014043103A1 (fr) 2012-09-11 2014-03-20 Coherus Biosciences, Inc. Étanercept correctement replié de pureté élevée avec un excellent rendement

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072060A2 (fr) * 2002-02-27 2003-09-04 Immunex Corporation Preparation de polypeptides
US20080213282A1 (en) * 2006-12-21 2008-09-04 Jaby Jacob Formulations
WO2011141926A2 (fr) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited PRÉPARATION LIQUIDE DE POLYPEPTIDES CONTENANT UN DOMAINE Fc D'UNE IMMUNOGLOBULINE
WO2012143418A1 (fr) * 2011-04-20 2012-10-26 Sandoz Ag Formulations liquides pharmaceutiques stables de la protéine de fusion tnfr:fc
WO2013006454A1 (fr) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Compositions de polypeptide de fusion tnfr:fc exempt d'arginine et leurs procédés d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDREAS ZIMMER: "Galenische Formulierung rekombinanter Wirkstoffe: Problem Arzneistoffstabilität", PHARMAZIE IN UNSERER ZEIT, vol. 32, no. 5, 1 September 2003 (2003-09-01), pages 384 - 389, XP055109543, ISSN: 0048-3664, DOI: 10.1002/pauz.200300037 *
GOKARN Y R ET AL: "Excipients for protein drugs", 1 January 2006, EXCIPIENT DEVELOPMENT FOR PHARMACEUTICAL, BIOTECHNOLOGY, AND DRUG DELIVERY SYSTEMS,, PAGE(S) 291 - 331, XP009179656 *
None *
See also references of WO2013059406A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2869817A1 (fr) * 2012-07-09 2015-05-13 Coherus Biosciences, Inc. Formulations aqueuses stables d'étanercept

Also Published As

Publication number Publication date
WO2013059407A1 (fr) 2013-04-25
MX367054B (es) 2019-08-02
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
LT2768525T (lt) 2019-09-25
BR112014009087A2 (pt) 2017-04-18
JP6110393B2 (ja) 2017-04-05
US20130101640A1 (en) 2013-04-25
AU2012326082B2 (en) 2016-12-15
HK1200851A1 (en) 2015-08-14
US20200405865A1 (en) 2020-12-31
US10213508B2 (en) 2019-02-26
EP2768531A4 (fr) 2015-03-11
WO2013059408A1 (fr) 2013-04-25
MX2014004732A (es) 2015-05-15
JP2014530862A (ja) 2014-11-20
US20130108632A1 (en) 2013-05-02
AU2012326170A1 (en) 2014-04-24
US20190290765A1 (en) 2019-09-26
KR20140079491A (ko) 2014-06-26
HK1200722A1 (en) 2015-08-14
EP2768533A1 (fr) 2014-08-27
CA2851635A1 (fr) 2013-04-25
TW201325606A (zh) 2013-07-01
US20190216930A1 (en) 2019-07-18
IL231824A0 (en) 2014-05-28
AR088381A1 (es) 2014-05-28
TWI644681B (zh) 2018-12-21
BR112014009146A8 (pt) 2017-06-20
US20180125982A1 (en) 2018-05-10
CN103998061A (zh) 2014-08-20
KR20140097184A (ko) 2014-08-06
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
US10987405B2 (en) 2021-04-27
EA026410B1 (ru) 2017-04-28
BR112014009022A2 (pt) 2017-05-02
EA201490802A1 (ru) 2014-08-29
US9302002B2 (en) 2016-04-05
IL231828A0 (en) 2014-05-28
TW201325608A (zh) 2013-07-01
SG11201401517VA (en) 2014-09-26
EA025267B1 (ru) 2016-12-30
CA2851639C (fr) 2020-12-29
MX2019009176A (es) 2019-10-07
US20190314498A1 (en) 2019-10-17
US20190290768A1 (en) 2019-09-26
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (fr) 2015-06-26
JP2014530254A (ja) 2014-11-17
HK1200718A1 (en) 2015-08-14
EP2768535A1 (fr) 2014-08-27
US20160317667A1 (en) 2016-11-03
KR20200008021A (ko) 2020-01-22
SG11201401562RA (en) 2014-09-26
PT2768525T (pt) 2019-07-17
EP2768525A4 (fr) 2015-07-15
JP2014530864A (ja) 2014-11-20
AR088383A1 (es) 2014-05-28
MX2014004733A (es) 2015-05-15
CN104011073B (zh) 2017-08-25
US10888619B2 (en) 2021-01-12
EP2768533A4 (fr) 2015-03-11
KR102068462B1 (ko) 2020-01-22
JP2014530863A (ja) 2014-11-20
MX2014004725A (es) 2015-02-05
CA2851651A1 (fr) 2013-04-25
HUE045624T2 (hu) 2020-01-28
AR088379A1 (es) 2014-05-28
JP6113176B2 (ja) 2017-04-12
CN104010657A (zh) 2014-08-27
DK2768525T3 (da) 2019-07-22
SG11201401519RA (en) 2014-07-30
JP2014530256A (ja) 2014-11-17
EA025663B1 (ru) 2017-01-30
CA2851646A1 (fr) 2013-04-25
TW201325609A (zh) 2013-07-01
SG11201401563SA (en) 2014-09-26
JP2014530255A (ja) 2014-11-17
EA201490815A1 (ru) 2014-09-30
TW201325607A (zh) 2013-07-01
HRP20191215T1 (hr) 2019-10-04
AU2012326082A1 (en) 2014-04-24
JP6220788B2 (ja) 2017-10-25
AU2012326168A1 (en) 2014-04-24
US20130101584A1 (en) 2013-04-25
BR112014009131A2 (pt) 2017-06-13
HK1200720A1 (en) 2015-08-14
AR088380A1 (es) 2014-05-28
US20190290767A1 (en) 2019-09-26
IN2014CN02527A (fr) 2015-06-26
AU2012326170B2 (en) 2016-12-22
AU2012326171B2 (en) 2017-03-09
KR20140083037A (ko) 2014-07-03
WO2013059412A1 (fr) 2013-04-25
CA2851628A1 (fr) 2013-04-25
US10772963B2 (en) 2020-09-15
AU2012326080A1 (en) 2014-04-24
US20160199489A1 (en) 2016-07-14
EP2768854A4 (fr) 2015-03-11
CA2851639A1 (fr) 2013-04-25
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (fr) 2013-04-25
US11129876B2 (en) 2021-09-28
US20180193463A1 (en) 2018-07-12
AU2012326084B2 (en) 2016-12-15
US9943601B2 (en) 2018-04-17
EP2768535A4 (fr) 2015-03-11
US20190184017A1 (en) 2019-06-20
BR112014009073A2 (pt) 2017-05-09
TW201325610A (zh) 2013-07-01
IN2014CN02592A (fr) 2015-09-04
EP2768532A4 (fr) 2015-03-11
AU2012326080B2 (en) 2017-02-16
EA027325B1 (ru) 2017-07-31
EP2768532A1 (fr) 2014-08-27
IL231827A0 (en) 2014-05-28
EP2768531A1 (fr) 2014-08-27
JP6104922B2 (ja) 2017-03-29
AU2012326171A1 (en) 2014-04-24
CA2851642A1 (fr) 2013-04-25
AR088382A1 (es) 2014-05-28
CN104010654A (zh) 2014-08-27
US9770510B2 (en) 2017-09-26
TWI595883B (zh) 2017-08-21
US20190314500A1 (en) 2019-10-17
CY1121843T1 (el) 2020-07-31
EP2768525B1 (fr) 2019-06-19
IL231825A0 (en) 2014-05-28
WO2013059406A1 (fr) 2013-04-25
BR112014009031A2 (pt) 2017-05-09
EA201490801A1 (ru) 2014-09-30
KR20140091707A (ko) 2014-07-22
US11135267B2 (en) 2021-10-05
JP6199298B2 (ja) 2017-09-20
RS59179B1 (sr) 2019-10-31
CN104010654B (zh) 2017-10-27
CN104010658A (zh) 2014-08-27
EA201490803A1 (ru) 2014-09-30
HK1200721A1 (en) 2015-08-14
AU2012326168B2 (en) 2016-12-15
IL231826A0 (en) 2014-05-28
AU2012326084A1 (en) 2014-04-17
US10980885B2 (en) 2021-04-20
MX2014004726A (es) 2015-05-15
US20190290766A1 (en) 2019-09-26
MX2014004728A (es) 2015-05-15
CN103998060A (zh) 2014-08-20
PL2768525T3 (pl) 2019-10-31
SI2768525T1 (sl) 2019-10-30
TWI619504B (zh) 2018-04-01
EA201490804A1 (ru) 2014-09-30
IL231829A0 (en) 2014-05-28
KR102163150B1 (ko) 2020-10-08
KR20140091705A (ko) 2014-07-22
EP2768854A1 (fr) 2014-08-27
US10980884B2 (en) 2021-04-20
SG11201401567YA (en) 2014-07-30
BR112014009131A8 (pt) 2017-06-20
US10376588B2 (en) 2019-08-13
EA201490817A1 (ru) 2014-09-30
KR20140091706A (ko) 2014-07-22
TW201325611A (zh) 2013-07-01
CN103998060B (zh) 2016-12-21
US9801942B2 (en) 2017-10-31
JP6220789B2 (ja) 2017-10-25
US20190314499A1 (en) 2019-10-17
ES2734070T3 (es) 2019-12-04
US20130108633A1 (en) 2013-05-02
US20180028668A1 (en) 2018-02-01
WO2013059410A1 (fr) 2013-04-25
BR112014009146A2 (pt) 2017-06-13
MX2014004734A (es) 2015-05-15
US20190298837A1 (en) 2019-10-03
SG11201401576WA (en) 2014-10-30
AR088460A1 (es) 2014-06-11

Similar Documents

Publication Publication Date Title
US11135267B2 (en) Etanercept formulations stabilized with metal ions
US20190336601A1 (en) Etanercept Formulations Stabilized with Sodium Chloride

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140506

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150615

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/02 20060101ALI20150609BHEP

Ipc: A61K 38/19 20060101ALI20150609BHEP

Ipc: A61K 39/395 20060101AFI20150609BHEP

Ipc: A61K 47/18 20060101ALI20150609BHEP

17Q First examination report despatched

Effective date: 20170331

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COHERUS BIOSCIENCES, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20190117

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20191215

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012061259

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1144642

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190715

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2768525

Country of ref document: PT

Date of ref document: 20190717

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190708

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190717

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: TR-IP CONSULTING LLC, CH

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190619

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017749

Country of ref document: EE

Effective date: 20190709

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 31473

Country of ref document: SK

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20191215

Country of ref document: HR

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191215

Country of ref document: HR

Payment date: 20191007

Year of fee payment: 8

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2734070

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191204

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190402291

Country of ref document: GR

Effective date: 20191128

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E045624

Country of ref document: HU

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: ROUTE DU COUTSET 18, 1485 NUVILLY (CH)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012061259

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200603

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191215

Country of ref document: HR

Payment date: 20201015

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20201013

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191215

Country of ref document: HR

Payment date: 20211011

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211018

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191215

Country of ref document: HR

Payment date: 20221017

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20221027

Year of fee payment: 11

Ref country code: FR

Payment date: 20221021

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20221017

Year of fee payment: 11

Ref country code: SM

Payment date: 20221031

Year of fee payment: 11

Ref country code: SK

Payment date: 20221017

Year of fee payment: 11

Ref country code: SE

Payment date: 20221026

Year of fee payment: 11

Ref country code: RS

Payment date: 20221017

Year of fee payment: 11

Ref country code: RO

Payment date: 20221017

Year of fee payment: 11

Ref country code: NO

Payment date: 20221025

Year of fee payment: 11

Ref country code: MC

Payment date: 20221026

Year of fee payment: 11

Ref country code: LV

Payment date: 20221019

Year of fee payment: 11

Ref country code: LU

Payment date: 20221027

Year of fee payment: 11

Ref country code: LT

Payment date: 20221017

Year of fee payment: 11

Ref country code: IT

Payment date: 20221028

Year of fee payment: 11

Ref country code: IE

Payment date: 20221025

Year of fee payment: 11

Ref country code: GB

Payment date: 20221020

Year of fee payment: 11

Ref country code: FI

Payment date: 20221024

Year of fee payment: 11

Ref country code: ES

Payment date: 20221104

Year of fee payment: 11

Ref country code: EE

Payment date: 20221020

Year of fee payment: 11

Ref country code: DK

Payment date: 20221028

Year of fee payment: 11

Ref country code: DE

Payment date: 20221018

Year of fee payment: 11

Ref country code: CZ

Payment date: 20221013

Year of fee payment: 11

Ref country code: BG

Payment date: 20221028

Year of fee payment: 11

Ref country code: AT

Payment date: 20221025

Year of fee payment: 11

Ref country code: PT

Payment date: 20221014

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20221017

Year of fee payment: 11

Ref country code: PL

Payment date: 20221014

Year of fee payment: 11

Ref country code: IS

Payment date: 20221027

Year of fee payment: 11

Ref country code: HU

Payment date: 20221108

Year of fee payment: 11

Ref country code: HR

Payment date: 20221017

Year of fee payment: 11

Ref country code: GR

Payment date: 20221101

Year of fee payment: 11

Ref country code: CH

Payment date: 20221103

Year of fee payment: 11

Ref country code: BE

Payment date: 20221027

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20221027

Year of fee payment: 11

Ref country code: MK

Payment date: 20221018

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AL

Payment date: 20221107

Year of fee payment: 11